TOCA News and Press, Tocagen From 09/12/19

SAN DIEGO , Sept. 12, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade ...

The following slide deck was published by Tocagen Inc. in conjunction with this Read more ...

SAN DIEGO , Aug. 26, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced Marty Duvall , chief executive officer, will present and webcast at the Baird 2019 Global Healthcare Conference in New York on Wednesday, S...

The following slide deck was published by Tocagen Inc. in conjunction with their 2019 Q2 earnings Read more ...

Tocagen (NASDAQ: TOCA ): Q2 GAAP EPS of -$0.72 beats by $0.04 . More news on: Tocagen Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO , Aug. 8, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the second quarter ended June 30, 2019 . "We are making excellent progress towards a...

SAN DIEGO , Aug. 1, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2019 financial results and business progress on Thursday, August 8, 2019 , after the close of the U.S. f...

Editor's note: Seeking Alpha is proud to welcome Tridobe Biotech Investment as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » On M...

Did the Market Overreact to Tocagen’s Recent Announcement? Tocagen finished enrolling patients for its recurrent high grade glioma ( HGG ) clinical trial in November of 2018 and has been conducting this Phase 3 trial ever since. On May 21, Tocagen announced that an Independent Dat...

Gainers:  Synlogic (NASDAQ: SYBX ) +28% . Immuron (NASDAQ: IMRN ) +26% . B Communications (NASDAQ: BCOM ) +23% . Arcadia Biosciences (NASDAQ: RKDA ) +17% . Vuzix Corporation (NASDAQ: VUZI ) +14% . MagnaChip Semiconductor Corporation (NYSE: MX ) +13% . Osmotica Pharmaceuticals (N...